Sana programs near clinical milestones; SC451 IND and dosing expected
Sana said SC451 is targeting type 1 diabetes and an in vivo CAR T platform is focused on oncology. An IND filing and initial patient dosing for SC451 are expected this year, with pivotal data anticipated next year.
Key programs are advancing toward clinical trials, with SC451 targeting type 1 diabetes and an in vivo CAR T platform focused on oncology. IND filing and initial patient dosing for SC451 are expected this year, with pivotal data anticipated next year. Based…